Efficacy of Anakinra in Pericarditis: A Systematic Review.

Abstract

Inflammation of the pericardium is referred to as pericarditis, which can cause sharp chest pain and has a high chance of recurrence even after treatment. This review will explore anakinra, which is an interleukin-1 receptor antagonist, as a potential new treatment for pericarditis. The systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines by searching PubMed and GoogleScholar from the years 2012 to 2022. After applying inclusion and exclusion criteria, thorough screening, and quality appraisal, a total of eleven studies were included in the review; eight case reports and three clinical trials. All studies showed that 100 mg/day of anakinra caused a remarkable improvement in patient outcomes. In addition, the pericarditis resolved quicker and had a lower chance of recurrence in comparison to conventional therapy.

• Authors: Ameer Haider Cheema, Keyur Chaludiya, Maham Khalid, Marcellina Nwosu, Srujana Konka, Walter Y Agyeman, Aakash Bisht, Ankit Gopinath, Ana P Arcia Franchini
• Journal: Cureus (Cureus) Vol. 14 Issue 10 Pg. e29862 (Oct 2022) ISSN: 2168-8184 [Print] United States
• PMID: 36212270 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2022, Cheema et al.